Myriad has failed to stop Ambry offering genetic tests using the BRCA1 or BRCA2 genes, but Ambry raised a substantial question about the validity of the claims of Myriad’s patents, as MaryAnne Armstrong reports.
University of Utah Research Foundation et al v Ambry Genetics Corporation
On June 13, 2013, the US Supreme Court handed down a seminal decision for the biopharma industry in Association for Molecular Pathology v Myriad Genetics, Inc, 133 S. Ct. 2107 (2013) (Myriad). In the Myriad decision the court held that naturally occurring nucleic acid sequences are not patent-eligible subject matter because they are products of nature.
In addition, claiming nucleic acids as being “isolated” will not render the nucleic acids patent-eligible. The court, however, left open the question of whether claims directed to methods of using the nucleic acids may be patentable.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Myriad, University of Utah Research Foundation, Ambry, BRCA testing, BRCA genes